An overview of insulin therapy in pharmacotherapy of diabetes mellitus type I
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20180418Keywords:
Insulin, Insulin therapy, Pharmacotherapy, Diabetes mellitus type IAbstract
Type 1 diabetes mellitus is a chronic disease, which characterizes itself with body’s inability to produce insulin from pancreas. This condition can happen from different autoimmune processes, which subsequently leads into destruction of beta cells in pancreas, the cells responsible for production of insulin. This condition account for about 5-10% of all different forms of diabetes, which should be taken very seriously since its incidence seems to be increasing worldwide and it can result in different devastating short and long-term complications. Management and approaches in patients with type 1 DM is of major concern worldwide since in the lack of proper management these patients cannot survive. Therefore, it is very important to have a multidisciplinary health management team that can have full focus on every aspect of this condition from continuous glucose monitoring, meal planning, screening for different complications to insulin therapy, which is the mainstay in treatment of patients in this group. American Diabetes Association (ADA) suggests using patient’s age in establishment of glycaemic goals, with targets for pre-prandial, bedtime and haemoglobin A1c levels. It is very important to educate patients on how to adjust the level of their insulin injection according to the amount of carbohydrate intake, premeal blood glucose, and anticipated activity. Insulin is and will remain the most important treatment approach in patients suffering from type 1 DM. According to recommendations of ADA, it is best when patients with type 1 DM are treated with multiple daily doses of insulin injections, such as three to four daily basal and prandial injections, or continuous subcutaneous insulin infusion devices should be used.References
Chiang JL, Kirkman MS, Laffel LMB, Peters AL. Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association. Diabetes Care. 2014;37(7):2034-54.
Abel M, Krokowski M. Pathophysiology of immune-mediated (type 1) diabetes mellitus: potential for immunotherapy. BioDrugs. 2001;15(5):291-301.
Noble JA, Valdes AM. Genetics of the HLA region in the prediction of type 1 diabetes. Current diabetes reports. 2011;11(6):533-42.
Tillil H, Kobberling J. Age-corrected empirical genetic risk estimates for first-degree relatives of IDDM patients. Diabetes. 1987;36(1):93-9.
Knip M, Simell O. Environmental triggers of type 1 diabetes. Cold Spring Harb Perspect Med. 2012;2(7):a007690.
Rosenbauer J, Herzig P, von Kries R, Neu A, Giani G. Temporal, seasonal, and geographical incidence patterns of type I diabetes mellitus in children under 5 years of age in Germany. Diabetol. 1999;42(9):1055-9.
Imkampe AK, Gulliford MC. Trends in Type 1 diabetes incidence in the UK in 0- to 14-year-olds and in 15- to 34-year-olds, 1991-2008. Diabet Med. 2011;28(7):811-4.
Harjutsalo V, Forsblom C, Groop P-H. Time trends in mortality in patients with type 1 diabetes: nationwide population based cohort study. BMJ. 2011;343.
Silverstein J, Klingensmith G, Copeland K, Plotnick L, Kaufman F, Laffel L, et al. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care. 2005;28(1):186-212.
Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33 Suppl 1:S62-9.
Rorsman P, Braun M. Regulation of insulin secretion in human pancreatic islets. Annu Rev Physiol. 2013;75:155-79.
Dimitriadis G, Mitrou P, Lambadiari V, Maratou E, Raptis SA. Insulin effects in muscle and adipose tissue. Diabetes Res Clin Pract. 2011;93 Suppl 1:S52-9.
Piłaciński S, Zozulińska-Ziółkiewicz DA. Influence of lifestyle on the course of type 1 diabetes mellitus. Arch Med Sci. 2014;10(1):124-34.
Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance. New England J Med. 2001;344(18):1343-50.
Donner T. Insulin – Pharmacology, Therapeutic Regimens and Principles of Intensive Insulin Therapy. Endotext. 2000: 1–3.
Garg S, Ampudia-Blasco FJ, Pfohl M. Rapid-acting insulin analogues in Basal-bolus regimens in type 1 diabetes mellitus. Endocr Pract. 2010;16(3):486-505.
Tricco AC, Ashoor HM, Antony J, Beyene J, Veroniki AA, Isaranuwatchai W, et al. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis. BMJ. 2014;349:g5459.
Eugenia G, Ashish S, Albert F. Review: Pharmacological and non-pharmacological treatment of endothelial dysfunction: relevance to diabetes. The British J Diabet Vasc Dis. 2007;7(1):5-10.
Westerberg DP. Diabetic ketoacidosis: evaluation and treatment. Am fam physician. 2013;87(5):337-46.
Buysschaert M, Dramais AS, Wallemacq PE, Hermans MP. Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care. 2000;23(12):1816-22.
American Diabetes Association, “2016 American Diabetes Association (ADA) Diabetes Guidelines Summary Recommendation from NDEI,” Natl Diabetes Educ Initiat. 2016;(39):1-46.
Yeh HC, Brown TT, Maruthur N, Ranasinghe P, Berger Z, Suh YD, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Annals int med. 2012;157(5):336-47.
Katzung BG, Masters SB, Trevor AJ. Basic & clinical pharmacology. McGraw-Hill Education, USA; 2012.